Vaidyanathan K, Kumar P, Reddy C O, Deshmane V, Somasundaram K, Mukherjee G
Department of Microbiology and Cell Biology, Indian Institute of Science, Bangalore-12, India.
Indian J Cancer. 2010 Jan-Mar;47(1):8-15. doi: 10.4103/0019-509X.58852.
Overexpression of the epidermal growth factor receptor family genes, which include ErbB-1, 2, 3 and 4, has been implicated in a number of cancers. We have studied the extent of ErbB-2 overexpression among Indian women with sporadic breast cancer.
Immunohistochemistry and genomic polymerase chain reaction (PCR) were used to study the ErbB2 overexpression. ErbB2 status was correlated with other clinico-pathological parameters, including patient survival.
ErbB-2 overexpression was detected in 43.2% (159/368) of the cases by immunohistochemistry. For a sub-set of patients (n = 55) for whom total DNA was available, ErbB-2 gene amplification was detected in 25.5% (14/55) of the cases by genomic PCR. While the ErbB2 overexpression was significantly higher in patients with lymphnode (chi2 = 12.06, P < or = 0.001), larger tumor size (chi2 = 8.22, P = 0.042) and ductal carcinoma (chi2 = 15.42, P < or = 0.001), it was lower in patients with disease-free survival (chi2 = 22.13, P < or = 0.001). Survival analysis on a sub-set of patients for whom survival data were available (n = 179) revealed that ErbB-2 status (chi2 =25.94, P < or = 0.001), lymphnode status (chi2 = 12.68, P < or = 0.001), distant metastasis (chi2 = 19.49, P < or = 0.001) and stage of the disease (chi2 = 28.04, P < or = 0.001) were markers of poor prognosis.
ErbB-2 overexpression was significantly greater compared with the Western literature, but comparable to other Indian studies. Significant correlation was found between ErbB-2 status and lymphnode status, tumor size and ductal carcinoma. ErbB-2 status, lymph node status, distant metastasis and stage of the disease were found to be prognostic indicators.
表皮生长因子受体家族基因（包括ErbB-1、2、3和4）的过表达与多种癌症有关。我们研究了印度散发性乳腺癌女性中ErbB-2过表达的程度。
采用免疫组织化学和基因组聚合酶链反应（PCR）研究ErbB2过表达情况。将ErbB2状态与其他临床病理参数（包括患者生存率）进行关联分析。
免疫组织化学检测发现43.2%（159/368）的病例存在ErbB-2过表达。对于可获得总DNA的一部分患者（n = 55），基因组PCR检测发现25.5%（14/55）的病例存在ErbB-2基因扩增。ErbB2过表达在有淋巴结转移的患者（χ2 = 12.06，P≤0.001）、肿瘤较大的患者（χ2 = 8.22，P = 0.042）和导管癌患者（χ2 = 15.42，P≤0.001）中显著更高，而在无病生存期患者中较低（χ2 = 22.13，P≤0.001）。对可获得生存数据的一部分患者（n = 179）进行生存分析发现，ErbB-2状态（χ2 = 25.94，P≤0.001）、淋巴结状态（χ2 = 12.68，P≤0.001）、远处转移（χ2 = 19.49，P≤0.001）和疾病分期（χ2 = 28.04，P≤0.001）是预后不良的标志物。
与西方文献相比，ErbB-2过表达明显更高，但与其他印度研究结果相当。发现ErbB-2状态与淋巴结状态、肿瘤大小和导管癌之间存在显著相关性。发现ErbB-2状态、淋巴结状态、远处转移和疾病分期是预后指标。
